Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018
Karthik Ramasamy(Oxford University Hospitals NHS Trust), Rafael Pinedo‐Villanueva(Nuffield Orthopaedic Centre), Neil Rabin(University College London), Rosemarie Finley(Myeloma UK), Daniel Prieto‐Alhambra(Nuffield Orthopaedic Centre), Mark T. Drayson(Institute of Immunology), Matthew Streetly(King's College - North Carolina), Bhuvan Kishore(National Health Service), M K Javaid(Nuffield Orthopaedic Centre), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Andrew Chantry(University of Sheffield), Stella Bowcock(King's College Hospital), Cyrus Cooper(University Hospital Southampton NHS Foundation Trust), Guido Nador(Oxford University Hospitals NHS Trust), John Ashcroft(Leeds Teaching Hospitals NHS Trust), Spyros Kolovos(IQVIA (United Kingdom))
Cited by 1
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
|European Heart Journal|2021|1.7k
Common genetic determinants of vitamin D insufficiency: a genome-wide association study
|The Lancet|2010|1.5k
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
|Osteoporosis International|2007|1.2k
Association of Cardiometabolic Multimorbidity With Mortality
|JAMA|2015|1.2k